COMMUNIQUÉS West-GlobeNewswire

Intuitive Surgical Announces First Quarter Earnings

17/04/2018 - 22:05

SUNNYVALE, Calif., April 17, 2018 (GLOBE NEWSWIRE) -- Intuitive Surgical, Inc. (“Intuitive”) (Nasdaq: ISRG ), a global technology leader in robotic-assisted, minimally invasive surgery, today announced financial results [...]

GenMark Diagnostics Schedules First Quarter Financial Results Conference Call for May 1, 2018

17/04/2018 - 22:03

CARLSBAD, Calif., April 17, 2018 (GLOBE NEWSWIRE) -- GenMark Diagnostics, Inc. (NASDAQ: GNMK ) today announced that it plans to release its first quarter earnings results after market close on Tuesday, May 1, 2018. [...]

Novartis presents first-of-its-kind evidence at AAN reinforcing robust and consistent efficacy of AimovigTM* (erenumab) for migraine patients with multiple treatment failures

17/04/2018 - 22:01

The LIBERTY trial studied patients with episodic migraine who had failed 2 to 4 prior treatments, a uniquely difficult-to-treat population often excluded from migraine prevention trials Patients taking erenumab had [...]

Aeglea BioTherapeutics Announces Proposed Public Offering of Common Stock

17/04/2018 - 22:01

AUSTIN, Texas, April 17, 2018 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc. (Nasdaq: AGLE ), a clinical-stage biotechnology company that designs and develops innovative human enzyme therapeutics for patients with [...]

Aduro Biotech Highlights Preclinical Data for Three Programs Reported at the American Association for Cancer Research Annual Meeting

17/04/2018 - 22:01

BERKELEY, Calif., April 17, 2018 (GLOBE NEWSWIRE) -- Aduro Biotech, Inc. (NASDAQ: ADRO ) today announced that data from three of the company’s programs were presented at the American Association for Cancer Research ( [...]

Nature's No. 1 Sustainably – strategy update

17/04/2018 - 20:19

Company announcement No. 08 / 2018 Attachment No 08 Natures no1 sustainably

INNATE PHARMA : Promising anti-tumor activity of monalizumab with cetuximab in SCCHN

17/04/2018 - 20:01

preliminary data suggest promising anti-tumor activity of the combination of monalizumab and cetuximab in patients with platinum pretreated SCCHN 8 partial responses (PR) among 26 patients evaluable for efficacy - [...]

INNATE PHARMA : Données préliminaires d'activité prometteuses pour la combinaison monalizumab et cetuximab dans le SCCHN

17/04/2018 - 20:01

DONNÉES PRÉLIMINAIRES D'ACTIVITÉ PROMETTEUSES POUR LA COMBINAISON DE MONALIZUMAB ET CETUXIMAB CHEZ DES PATIENTS ATTEINTS D'UN CANCER DE LA TÊTE ET DE COU ET PRÉTRAITÉS PAR SELS DE PLATINE Huit réponses partielles (PR) [...]

AACR annual meeting 2018: Nanobiotix presented preclinical data showing NBTXR3 nanoparticles can activate the cGAS-STING pathway

17/04/2018 - 20:01

AACR ANNUAL MEETING 2018: NANOBIOTIX PRESENTED PRECLINICAL DATA SHOWING NBTXR3 NANOPARTICLES CAN ACTIVATE THE cGAS-STING PATHWAY Paris, France and Cambridge, Massachusetts, April 17, 2018 - NANOBIOTIX (Euronext: NANO - [...]

AACR annual meeting 2018: Nanobiotix a presenté des données précliniques montrant que les nanoparticules NBTXR3 peuvent activer la voie cGAS-STING

17/04/2018 - 20:01

AACR ANNUAL MEETING 2018: NANOBIOTIX A PRESENTE DES DONNEES PRECLINIQUES MONTRANT QUE LES NANOPARTICULES NBTXR3 PEUVENT ACTIVER LA VOIE cGAS-STING Paris, France et Cambridge, Massachusetts, USA, 17 avril, 2018 - [...]

Aptose Presents Preclinical Data on APTO-253 at 2018 AACR Annual Meeting

17/04/2018 - 20:00

Cancer cells deficient in BRCA1 or BRCA2 function hyper-sensitive to APTO-253 CHICAGO and SAN DIEGO and TORONTO, April 17, 2018 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (NASDAQ: APTO ) (TSX: APS ) today announced the [...]

Durham College and GrowWise Health partner to develop Cannabis Industry Specialization certificate

17/04/2018 - 19:30

First-of-its-kind program will prepare business professionals to join Canada’s cannabis industry OSHAWA, Ontario, April 17, 2018 (GLOBE NEWSWIRE) -- Durham College (DC) and Emblem Corp. (TSXV:EMC) (EMC.WT) (Emblem), on [...]

Ultragenyx and Kyowa Kirin Announce FDA Approval of Crysvita® (burosumab-twza) for the Treatment of Children and Adults with X–Linked Hypophosphatemia (XLH)

17/04/2018 - 19:25

First Approved Therapy for XLH in the U.S. ; Only Treatment that Targets the Underlying Cause of this Rare, Hereditary, Lifelong Disease Ultragenyx to Host Conference Call Today at 4:30 pm Eastern Time NOVATO, Calif. [...]

Mersana Therapeutics Presents Preclinical Data Further Demonstrating Differentiating Aspects of Its ADC Platform Technology at AACR 2018

17/04/2018 - 19:01

Detailed Characterization of Unique DolaLock Technology Enhancements to Drug Efficacy and Tolerability XMT-1522 Demonstrates Synergy in Combination with a Checkpoint Inhibitor CAMBRIDGE, Mass., April 17, 2018 (GLOBE [...]

Bavarian Nordic A/S - Report on the Results of the Annual General Meeting, held April 17, 2018

17/04/2018 - 17:52

COPENHAGEN, Denmark, April 17, 2018 - Bavarian Nordic A/S (OMX: BAVA, OTC: BVNRY) today held the Annual General Meeting with the results as follows: The Annual Report for 2017 was adopted. The Board of Directors' [...]

Annual General Meeting 2018: Tecan shareholders endorse all motions proposed by the Board of Directors

17/04/2018 - 17:46

Increase in the dividend from CHF 1.75 to CHF 2.00 per share Lukas Braunschweiler and Daniel R. Marshak elected as new members of the Board of Directors Lukas Braunschweiler elected as new Chairman of Tecan Heinrich [...]

Diaxonhit et Vatel Direct annoncent une levée de fonds obligataire d'un montant de 2,5 millions d'euros

17/04/2018 - 17:46

Diaxonhit et Vatel Direct annoncent une levée de fonds obligataire de 2,5 millions d'euros Vatel Direct clôture avec succès sa 9 ème levée de fonds en récoltant 2 499 947,44 € Paris, le 17 avril 2018 - Diaxonhit ( [...]

Olainfarm’s Sales in March Exceed 10 Million Euros.

17/04/2018 - 17:14

17 th April, 2018 Olainfarm’s Sales in March Exceed 10 Million Euros. Preliminary three months consolidated sales results show 13% sales increase. Consolidated sales in March Preliminary consolidated results of AS [...]

Medtronic Expands Focus on Interventional Oncology with Its U.S. Launch of OptiSphere(TM) Embolization Spheres

17/04/2018 - 17:01

Product Line Offers Unique, Resorbable Option for Patients with Hypervascular Tumors DUBLIN - April 17, 2018 - Medtronic plc (NYSE: MDT) today announced its U.S. launch of OptiSphere(TM) embolization spheres, a [...]